Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 8/20 | 0.57 |
| ▸ | MMP9 | P14780 | 6/20 | 0.39 |
| ▸ | MMP2 | P08253 | 5/20 | 0.39 |
| ▸ | MMP8 | P22894 | 4/20 | 0.39 |
| ▸ | MMP13 | P45452 | 4/20 | 0.39 |
| ▸ | PLG | P00747 | 3/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437339 | 0.88 | PLAU (0.59) | PLAUPLGNAMPTPLATHTT | |
| Hydrochloric Acid SCHEMBL6433049 | 0.87 | PLAU (0.71) | PLAUMMP9MMP2MMP8MMP13 | |
| SCHEMBL6433837 | 0.80 | PLAU (0.51) | PLAUPLGPLAT | |
| Hydrochloric Acid SCHEMBL7588121 | 0.79 | PLAU (0.48) | PLAUMMP9MMP2MMP13PLG | |
| SCHEMBL7373509 | 0.78 | HCRTR2 (0.37) | PLAURORC | |
| SCHEMBL6435181 | 0.77 | PLAU (0.44) | PLAUMMP9MMP2MMP8MMP13 | |
| Hydrochloric Acid SCHEMBL7449769 | 0.77 | PLAU (0.44) | PLAUMMP9MMP2MMP13ADAM17 | |
| SCHEMBL7367873 | 0.77 | PLAU (0.33) | PLAURORC | |
| Hydrochloric Acid SCHEMBL6437367 | 0.76 | PLAU (0.49) | PLAUMMP9MMP2MMP8PLG | |
| Hydrochloric Acid SCHEMBL6433996 | 0.76 | PLAU (0.49) | PLAUMMP9MMP2MMP8PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLAU 119/4885MMP9 44/4885MMP2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.